Nifedipine
Product Images NDC 0904-7080

Product Visual Gallery

This gallery contains 7 technical images submitted to the FDA as part of the official labeling for Nifedipine (NDC 0904-7080). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Major Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

0b564dde 2149 4f5c 900b 301a95138a61 00

This is a product label for Nifedipine extended-release tablets, a prescription medication used to treat hypertension and angina. The label includes the drug's National Drug Code (NDC) number, dosage, and quantity. The remaining text is not clear and appears to be gibberish.*

FDA Label Image

0b564dde 2149 4f5c 900b 301a95138a61 01

NIFEdipine Extended-Release tablets are sold in bottles of 100 units. Each tablet is extended-release and contains 80mg of NIFEdipine. This medication requires a prescription to be filled and should be kept out of reach of children. The manufacturer is Major Pharmaceuticals. The listed NDC number is 0904-7081-61.*

FDA Label Image

0b564dde 2149 4f5c 900b 301a95138a61 02

This is a description of two different drugs for hypertension. The first drug has a National Drug Code (NDC) of 0904-7080-61 and contains 100 unit dose tablets. The drug is Nifedipine, an extended-release medication in tablet form. The second drug has an NDC of 0904-7080-81 and contains 30mg of Nifedipine. The instructions state to swallow the extended-release tablets whole and not divided. The location and manufacturer information is unclear.*

FDA Label Image

01 (Image 01)

FDA Label Image

02 (Image 02)

This is a table showing the adverse effects of Nifedipine extended-release tablets versus a placebo, based on a sample size of 707 and 266 respectively. Adverse effects include headache, fatigue, dizziness, constipation, and nausea. Percentages of occurrence are provided for each adverse effect.*

FDA Label Image

03 (Image 03)

This is a table that shows the percentage of adverse effects reported during a clinical trial comparing the use of Nifedipine capsules to a placebo. The trial had 226 participants using the capsules and 235 using the placebo. The adverse effects reported are dizziness, lightheadedness, giddiness, flushing, heat sensation, headache, weakness, nausea, heartburn, muscle cramps, tremor, peripheral edema, nervousness, mood changes, palpitations, dyspnea, cough, wheezing, nasal congestion, and sore throat.*

FDA Label Image

04 (Image 04)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.